Introduction: Cardiovascular disease is a leading cause of death worldwide; post-infarction injury involves oxidative stress and inflammation. Cardioprotective leads from marine sponges need early screening for cardiac ion-channel liability, because block of the human ether-à-go-go-related gene (hERG) channel prolongs the QT interval and may provoke fatal arrhythmia. For Indonesian Haliclona caerulea, neither the metabolite profile nor its cardiac target space has been reported. Objectives: To profile metabolites of the n-hexane fraction of H. caerulea, predict their myocardial infarction targets, and screen them for hERG liability as a safety filter, not a therapeutic target. Methods: The fraction was analyzed by untargeted LC–MS/MS and metabolites putatively annotated. Drug-likeness and toxicity were predicted with MolSoft, SwissADME, and ADMETlab 3.0. Candidates were docked into the hERG pore (PDB 8ZYP), benchmarked by re-docking E-4031. Targets came from SwissTargetPrediction, TargetNet, and SEA; disease genes from GeneCards. Results: All seven metabolites met drug-likeness criteria and returned low ligand-based probabilities (< 0.7) for hERG inhibition, mutagenicity, and carcinogenicity. Docking nevertheless placed neopetrocyclamine A (–11.03 kcal/mol) and adociasulfate 6 (–10.04 kcal/mol) at the E-4031 site with affinities exceeding the blocker, contradicting that result. Network analysis identified 132 shared and ten hub genes. Conclusion: The target network supports putative cardioprotective interest, whereas docking flags the two strongest pore binders as carrying an unresolved proarrhythmic liability requiring experimental validation.
Copyrights © 2026